Affymetrix Launches 18 New Microarrays for Gene Expression Analysis of Model and Applied Research Organisms
October 06 2011 - 4:00PM
Business Wire
Affymetrix®, Inc. (NASDAQ: AFFX) today announced
commercialization of 18 new array designs for whole-transcriptome
analysis of model and applied research organisms that will allow
scientists to obtain a more complete gene expression view than
traditional 3’ biased arrays. The new Affymetrix®
Gene 1.1 ST Array Strips are created exclusively for the
GeneAtlas® System—the first personal bench-top
microarray system in which four samples can be processed
simultaneously. The GeneAtlas System and array strips offer an
affordable solution that combines excellent performance and a
simplified workflow with intuitive, easy-to-use software.
Affymetrix Gene 1.1 ST Array Strips
(Photo: Business Wire)
The Gene 1.1 ST Arrays, developed with leading researchers to
enable rapid advancement in genetic research, offer unique array
designs based on the most recent genome builds and the highest
probe coverage currently available. Probes are distributed across
the full length of the gene, providing a more complete and accurate
picture of overall gene expression−in contrast to other array
providers using a single probe localized at the extreme 3’.
Whole-transcriptome analysis enables researchers to detect multiple
transcript isoforms from a given gene, including those that could
be missed using a 3’-biased expression design, such as splice
variants, non-polyadenylated transcripts, transcripts with
alternative polyadenylation sites, and truncated transcripts.
“The new Zebrafish Array design is a significant update,” said
Leonard Zon, Director of Stem Cell Research Program, and Yi Zhou,
Genomic Core Director of the Stem Cell Research Program at
Children's Hospital Boston and Harvard Medical School in Boston.
“The gene content is based on most recent sequence collection from
Zv9, VEGA, RefSeq, and ESTs. The latest probe selection and design
algorithms were used to include all exons that represent entire
transcripts and known splicing variants. The array design contains
more than 52,000 transcript sequences−three times
more than the previous design. This new array design has
facilitated our gene expression studies on mutants and
purified cell populations, and the sub microgram RNA input
requirement allowed us to perform pathway analysis using a
small number of cells or embryos. The comprehensive and updated
coverage of the transcriptome will enable comparative studies of
gene expression regulation networks between Zebrafish and mammals,
including human and mouse.”
The importance of the model and applied research organisms
continue to grow significantly today, fueled by the recent advances
of next-generation sequencing and genome–wide association studies,
and remains one of the fastest growing segments of life science
research. With the introduction of 18 new arrays, Affymetrix offers
researchers the most extensive menu of organisms available for
whole-transcriptome analysis, which is critical for comparative
genomic research, evolutionary biology studies, agricultural crop
improvements, and deciphering the molecular mechanisms underlying
human disease.
“Until now scientists were prevented from accessing a
whole-transcriptome view of their model organism due to the cost
and complexity of microarrays,” said Kevin Cannon, Vice President
of Gene Expression at Affymetrix. “The Affymetrix GeneAtlas
platform is the first complete microarray system to combine
affordability, ease of use, and rapid data analysis. The GeneAtlas
System, coupled with these 18 new model organism arrays, provides
scientists with a personalized system for sample control, the
newest content for discovery and observation, and simple data
analysis tools for faster publishing.”
The Affymetrix Gene 1.1 ST Array Strips are the latest
additions to the expanding portfolio of Affymetrix gene expression
microarrays offering whole-transcript coverage to meet the
scientific challenges of today and the future. To learn more about
these arrays and the GeneAtlas System go to
http://www.affymetrix.com
About Affymetrix
Affymetrix technology is used by the world's top pharmaceutical,
diagnostic, and biotechnology companies, as well as leading
academic, government and nonprofit research institutes. More than
2,100 systems have been shipped around the world and more than
23,500 peer-reviewed papers have been published using the
technology. Affymetrix is headquartered in Santa Clara, Calif., and
has manufacturing facilities in Santa Clara, Cleveland, Ohio, and
Singapore. The company has about 900 employees worldwide and
maintains sales and distribution operations across Europe, Asia,
and Latin America. For more information about Affymetrix, please
visit http://www.affymetrix.com.
Forward-looking statements
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements
regarding Affymetrix' "expectations," "beliefs," "hopes,"
"intentions," "strategies," or the like. Such statements are
subject to risks and uncertainties that could cause actual results
to differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix' Form 10-K for the
year ended December 31, 2010, and other SEC reports for subsequent
quarterly periods.
NOTE: Affymetrix, and the Affymetrix logo, are trademarks or
registered trademarks of Affymetrix, Inc.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50020214&lang=en
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Sep 2023 to Sep 2024